HEAD & NECK CANCERS

In an interview with Targeted Oncology, Ryan Carey, MD, and Rob Lee, PhD, discussed the preclinical research and the potential for lidocaine to kill certain cancer cells.

A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.

Toripalimab in combination with gemcitabine and cisplatin, as well as toripalimab monotherapy, has been granted approval by the FDA for patients with recurrent, unresectable, or metastatic nasopharyngeal carcinoma.

Modest but durable antitumor activity was observed with sacituzumab govitecan-hziy in the treatment of patients with metastatic or locally recurrent head and neck squamous cell carcinoma who received between 1 and 3 prior lines of therapy.

Two doses of CD40HVac, a therapeutic vaccine targeting dendritic cells, are being evaluated as treatment for HPV-positive oropharyngeal cancer in a phase 1/2a trial.

Patients with heavily pretreated head and neck cancer achieved an overall response rate of 24% with enfortumab vedotin in the phase 2 EV-202 study.

A coprimary end point in the phase 3 LEAP-010 study will not be met.

The FDA has approved avasopasem for patients with head and neck cancer to treat their radiotherapy-induced severe oral mucositis.

The phase 1b/2 ASP-1929-181 continues to investigate the photoimmunotherapy, ASP-1929, in combination with anti-EGFR therapy in patients with advanced head and neck cancer and other solid tumors.

Eftilagimod alpha plus pembrolizumab showed an overall response rate of over 25% in patients with metastatic head and neck squamous cell carcinoma treated in the phase 2 TACTI-002 study.

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck did not derive an overall response rate benefit with nivolumab and ipilimumab vs nivolumab alone.

For Head and Neck Cancer Awareness Month, we looked at the connection between the human papillomavirus and this disease, and the role it has in determining treatment now and in the future.

An analysis of 4 deidentified data sets revealed that HRAS mutations occurred in 3% to 4% of patients with head and neck squamous cell carcinoma.

HGF and c-MET inhibition with ficlatuzumab and cetuximab showed progression-free survival benefit in patients with pan-refractory recurrent or metastatic head and neck squamous cell carcinoma, according to phase 2 study data.

The FDA has granted a fast-track designation for RRx-001 and accepted the investigational new drug application for a phase 2b trial of severe oral mucositis in chemotherapy- and radiation-treated patients with head & neck cancer.

Based on findings from the phase 2b GT-201 and phase 3 ROMAN trials, the FDA has granted priority review to the new drug application for avasopasem manganese as a treatment for radiotherapy-induced severe oral mucositis in patients with head and neck cancer.

In an interview with Targeted Oncology, Everett E. Vokes, MD, discussed precision oncology for head and neck cancer and how the molecular biology of head and neck cancers is an opportunity for new investigations and treatment development.

The FDA has not made a decision on the approval application for toripalimab plus chemotherapy or toripalimab monotherapy for the treatment of advanced recurrent or metastatic nasopharyngeal carcinoma.

In an interview with Targeted Oncology, Jimmy Caudell, MD, PhD, discussed the biggest challenges being faced in the head and neck cancer space.

In an interview with Targeted Oncology, Allan Pickens, MD, discussed research on racial disparities in surgery for esophageal cancer.

In an interview with Targeted Oncology, Glenn J. Hanna, MD, discussed the phase 2 study evaluating treatment with nivolumab in patients with high-risk oral proliferative leukoplakia.

In a phase 1 study, a peptide conjugated vaccine showed potent immunogenicity and was able to induce functional T-cell responses in almost all vaccinated patients with HPV16-positive premalignancies.

Treatment with CUE-101 continued to show promise for patients with head and neck squamous cell carcinoma when combined with pembrolizumab or used as a monotherapy.

In an interview with Targeted Oncology, Marcin Dzienis, MD, further discussed the phase 4 trial of pembrolizumab plus carboplatin and paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Long-term follow-up of KEYNOTE-048 shows improvements in overall survival with pembrolizumab monotherapy and in combination for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Building on data showing its preclinical anti-tumor activity, CUE-101 will be examined in a phase 1b study and has been granted FDA fast track designation.

Patients with locally advanced head and neck squamous cell carcinoma did not show statistically significant improvement in event-free survival with pembrolizumab plus chemoradiation vs chemoradiation alone.

Improvement in overall survival for patients with locally advanced head and neck squamous cell carcinoma was demonstrated with xevinapant plus standard chemoradiotherapy vs matched placebo at the 5-year mark.

Erasca has entered into a clinical trial collaboration and supply agreement with Eli Lilly and Company to evaluate the anti-EGFR antibody cetuximab.